

Global Contraceptive Pills Market Report and Forecast 2023-2031

Market Report | 2023-04-18 | 147 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$5999.00
- Five User License \$7999.00
- Corporate License \$9999.00

Report description:

Global Contraceptive Pills Market Report and Forecast 2023-2031

Global Contraceptive Pills Market Outlook

The global contraceptive pills market size reached a value of USD 18.66 billion in 2022. The market is further expected to grow at a CAGR of 3.92% during the forecast period of 2023-2031, likely to attain a value of USD 26.35 billion by 2031. The growth of the market is likely to be driven by the rapid technological developments.

Contraceptive Pills Market: Introduction and Overview

Contraceptive pills are medications taken orally by people with a uterus to prevent pregnancy. They contain hormones, typically a combination of oestrogen and progestin, or just progestin alone, that work to prevent ovulation, thicken cervical mucus to prevent sperm from reaching the egg, and thin the lining of the uterus to make it less receptive to implantation. There are many different types and formulations of contraceptive pills available, and they must be prescribed by a healthcare provider. When used correctly and consistently, contraceptive pills are highly effective in preventing pregnancy.

The contraceptive pills market has numerous applications in women's health and family planning. The primary application is to prevent unintended pregnancy, but contraceptive pills are also used to regulate menstrual cycles, manage symptoms of polycystic ovary syndrome (PCOS), treat acne, and alleviate symptoms of endometriosis. Additionally, some types of contraceptive pills can be used for hormone replacement therapy (HRT) in people experiencing menopausal symptoms. Long-term use of contraceptive pills has been associated with a reduced risk of certain cancers, making them an important tool in cancer prevention. With the development of new and improved formulations of contraceptive pills, the potential applications of this market are likely to continue expanding.

Pros of contraceptive pills:

-[Highly effective: When taken correctly and consistently, contraceptive pills are up to 99% effective in preventing pregnancy.
 -[Easy to use: Contraceptive pills are easy to use and can be taken at home. They do not require any special equipment or training.
 -[Regulates menstrual cycle: Contraceptive pills can regulate the menstrual cycle and reduce menstrual pain, cramps, and heavy

bleeding.

-[Reduces the risk of some cancers: Studies have shown that long-term use of contraceptive pills can reduce the risk of ovarian and endometrial cancers.

-[]Can improve acne: Some types of contraceptive pills can improve acne by regulating hormones that cause acne. Cons of contraceptive pills:

- Requires daily use: Contraceptive pills must be taken every day at the same time, which can be a challenge for some people. - May cause side effects: Common side effects of contraceptive pills include nausea, headaches, weight gain, and mood changes. Some people may also experience more serious side effects, such as blood clots.

-[Does not protect against STIs: Contraceptive pills do not protect against sexually transmitted infections (STIs), so additional protection such as condoms may be needed.

- May not be suitable for everyone: Some people may not be able to use contraceptive pills due to underlying health conditions or other factors.

- Cost: The cost of contraceptive pills can vary depending on the brand and insurance coverage and can be a barrier for some people.

It is important to speak with a healthcare provider to determine if contraceptive pills are the best option for you, and to discuss potential risks and benefits.

Contraceptive Pills Market Segmentations

Market Breakup by Type - Progestin Pills Combination Pills o[]Monophasic o
Triphasic o∏Others Market Breakup by Drug Type -[]Generics Branded Market Breakup by Therapy Type - Monotherapy - Combined Contraceptives Market Breakup by Age Group -[15-45 Years - Above 45 Years Market Breakup by Distribution Channel - Hospital Pharmacy - Retail Pharmacy Online Channel - Public Channel -[Others Contraceptive Pills Market Breakup by Region North America United States of America -∏Canada - Europe United Kingdom -[]Germany -[]France - Italy

Others - Asia Pacific - China -[]]apan -[]India - ASEAN - Australia -- Latin America -∏Brazil Argentina Mexico -Middle East and Africa -∏Saudi Arabia - United Arab Emirates Nigeria - South Africa Others

Contraceptive Pills Market Scenario

The contraceptive pills market has been driven by several key factors, including increasing awareness and acceptance of contraceptives, the rise in the number of sexually active women, and government initiatives to promote family planning. Technological advancements in contraceptive pills have led to the development of new formulations with fewer side effects and higher efficacy rates, further driving demand. Growing female empowerment has also led to a higher demand for contraception, including contraceptive pills. In addition, the increasing incidence of sexually transmitted infections (STIs) has led many women to use contraceptive pills in combination with condoms, driving demand for both products. A trend in the market is the growing popularity of long-acting reversible contraceptives (LARCs) such as intrauterine devices (IUDs) and implants, which provide more long-term contraception and do not require daily use.

Additionally, the availability of over-the-counter emergency contraceptive pills (ECPs) has increased, making them more accessible to those who need them. Overall, the contraceptive pills market is expected to continue growing as more women seek effective and convenient contraception.

Key Players in the Global Contraceptive Pills Market

The report gives an in-depth analysis of the key players involved in the contraceptive pills market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

- Piramal Enterprises Ltd.
- Agile Therapeutics
- Johnson & Johnson Services, Inc.
- Abbive Inc.
- Merck & Co Inc.
- Teva Pharmaceuticals Industries Ltd.
- Bayer AG
- Pfizer Inc.

- -[]Helm AG.
- Reckitt Benckiser Group PLC
- Viatris Inc.
- Amneal Pharmaceuticals LLC
- -🛛 Bayer AG
- [Allergan plc.]
- Agile Therapeutics

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.2 Key Assumptions
 - 1.3 Report Coverage Key Segmentation and Scope
 - 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Contraceptive Pills Market Overview
 - 3.1 Global Contraceptive Pills Market Historical Value (2016-2022)
 - 3.2 Global Contraceptive Pills Market Forecast Value (2023-2031)
- 4 Global Contraceptive Pills Market Landscape
 - 4.1 Global Contraceptive Pills Developers Landscape
 - 4.1.1 Analysis by Year of Establishment
 - 4.1.2 Analysis by Company Size
 - 4.1.3 Analysis by Region
 - 4.2 Global Contraceptive Pills Product Landscape
 - 4.2.1 Analysis by Product Type
 - 4.2.2 Analysis by Drug Type
 - 4.2.3 Analysis by Age Group
 - 4.2.4 Analysis by Therapy Type
 - 4.2.5 Analysis by Distribution Channel
- 5 Global Contraceptive Pills Market Dynamics
 - 5.1 Market Drivers and Constraints
 - 5.2 SWOT Analysis
 - 5.3 Porter's Five Forces Model
 - 5.4 Key Demand Indicators
 - 5.5 Key Price Indicators
 - 5.6 Industry Events, Initiatives, and Trends
 - 5.7 Value Chain Analysis
- 6 Global Contraceptive Pills Market Segmentation
 - 6.1 Global Contraceptive Pills Market by Type
 - 6.1.1 Market Overview
 - 6.1.2 Progestin Pills
 - 6.1.3 Combination Pills
 - 6.1.3.1 Monophasic
 - 6.1.3.2 Triphasic
 - 6.1.3.3 Others
 - 6.2 Global Contraceptive Pills Market by Drug Type
 - 6.2.1 Market Overview

- 6.2.2 Generics
- 6.2.3 Branded
- 6.3 Global Contraceptive Pills Market by Therapy Type
 - 6.3.1 Market Overview
 - 6.3.2 Monotherapy
 - 6.3.3 Combined Contraceptives
- 6.4 Global Contraceptive Pills Market by Age Group
- 6.4.1 Market Overview
- 6.4.2 15-45 Years
- 6.4.3 Above 45 Years
- 6.5 Global Contraceptive Pills Market by Distribution Channel
 - 6.5.1 Market Overview
 - 6.5.2 Hospital Pharmacy
 - 6.5.3 Retail Pharmacy
 - 6.5.4 Online Channel
 - 6.5.5 Public Channel
 - 6.5.6 Others
- 6.6 Global Contraceptive Pills Market by Region
 - 6.6.1 Market Overview
 - 6.6.2 North America
 - 6.6.3 Europe
 - 6.6.4 Asia Pacific
 - 6.6.5 Latin America
 - 6.6.6 Middle East and Africa
- 7 North America Contraceptive Pills Market
 - 7.1 Market Share by Country
 - 7.2 United States of America
 - 7.3 Canada
- 8 Europe Contraceptive Pills Market
 - 8.1 Market Share by Country
 - 8.2 United Kingdom
 - 8.3 Germany
 - 8.4 France
 - 8.5 Italy
 - 8.6 Others
- 9 Asia Pacific Contraceptive Pills Market
 - 9.1 Market Share by Country
 - 9.2 China
 - 9.3 Japan
 - 9.4 India
 - 9.5 ASEAN
 - 9.6 Australia
 - 9.7 Others
- 10 Latin America Contraceptive Pills Market
 - 10.1 Market Share by Country
 - 10.2 Brazil
 - 10.3 Argentina

Scotts International. EU Vat number: PL 6772247784

- 10.4 Mexico
- 10.5 Others
- 11 Middle East and Africa Contraceptive Pills Market
 - 11.1 Market Share by Country
 - 11.2 Saudi Arabia
 - 11.3 United Arab Emirates
 - 11.4 Nigeria
 - 11.5 South Africa
 - 11.6 Others
- 12 Patent Analysis
 - 12.1 Analysis by Type of Patent
 - 12.2 Analysis by Publication year
 - 12.3 Analysis by Issuing Authority
 - 12.4 Analysis by Patent Age
 - 12.5 Analysis by CPC Analysis
 - 12.6 Analysis by Patent Valuation
 - 12.7 Analysis by Key Players
- 13 Grants Analysis
 - 13.1 Analysis by year
 - 13.2 Analysis by Amount Awarded
 - 13.3 Analysis by Issuing Authority
 - 13.4 Analysis by Grant Application
 - 13.5 Analysis by Funding Institute
 - 13.6 Analysis by NIH Departments
 - 13.7 Analysis by Recipient Organization
- 14 Funding Analysis
 - 14.1 Analysis by Funding Instances
 - 14.2 Analysis by Type of Funding
 - 14.3 Analysis by Funding Amount
 - 14.4 Analysis by Leading Players
 - 14.5 Analysis by Leading Investors
 - 14.6 Analysis by Geography
- 15 Partnership and Collaborations Analysis
 - 15.1 Analysis by Partnership Instances
 - 15.2 Analysis by Type of Partnership
 - 15.3 Analysis by Leading Players
 - 15.4 Analysis by Geography
- 16 Regulatory Framework
- 16.1 Regulatory Overview
 - 16.1.1 US FDA
 - 16.1.2 EU EMA
 - 16.1.3 INDIA CDSCO
 - 16.1.4 JAPAN PMDA
 - 16.1.5 Others
- 17 Supplier Landscape
 - 17.1 Piramal Enterprises Ltd.
 - 17.1.1 Financial Analysis

Scotts International. EU Vat number: PL 6772247784

- 17.1.2 Product Portfolio
- 17.1.3 Demographic Reach and Achievements
- 17.1.4 Mergers and Acquisitions
- 17.1.5 Certifications
- 17.2 Agile Therapeutics
 - 17.2.1 Financial Analysis
 - 17.2.2 Product Portfolio
 - 17.2.3 Demographic Reach and Achievements
 - 17.2.4 Mergers and Acquisitions
 - 17.2.5 Certifications
- 17.3 Johnson & Johnson Services, Inc.
 - 17.3.1 Financial Analysis
 - 17.3.2 Product Portfolio
 - 17.3.3 Demographic Reach and Achievements
 - 17.3.4 Mergers and Acquisitions
 - 17.3.5 Certifications
- 17.4 Abbive Inc.
 - 17.4.1 Financial Analysis
 - 17.4.2 Product Portfolio
 - 17.4.3 Demographic Reach and Achievements
 - 17.4.4 Mergers and Acquisitions
 - 17.4.5 Certifications
- 17.5 Merck & Co Inc.
 - 17.5.1 Financial Analysis
 - 17.5.2 Product Portfolio
 - 17.5.3 Demographic Reach and Achievements
 - 17.5.4 Mergers and Acquisitions
 - 17.5.5 Certifications
- 17.6 Teva Pharmaceuticals Industries Ltd.
 - 17.6.1 Financial Analysis
 - 17.6.2 Product Portfolio
 - 17.6.3 Demographic Reach and Achievements
 - 17.6.4 Mergers and Acquisitions
 - 17.6.5 Certifications
- 17.7 Bayer AG
 - 17.7.1 Financial Analysis
 - 17.7.2 Product Portfolio
 - 17.7.3 Demographic Reach and Achievements
 - 17.7.4 Mergers and Acquisitions
 - 17.7.5 Certifications
- 17.8 Pfizer Inc.
 - 17.8.1 Financial Analysis
 - 17.8.2 Product Portfolio
 - 17.8.3 Demographic Reach and Achievements
 - 17.8.4 Mergers and Acquisitions
 - 17.8.5 Certifications
- 17.9 Helm AG.

Scotts International. EU Vat number: PL 6772247784

- 17.9.1 Financial Analysis
- 17.9.2 Product Portfolio
- 17.9.3 Demographic Reach and Achievements
- 17.9.4 Mergers and Acquisitions
- 17.9.5 Certifications
- 17.10 Reckitt Benckiser Group PLC
 - 17.10.1 Financial Analysis
 - 17.10.2 Product Portfolio
 - 17.10.3 Demographic Reach and Achievements
 - 17.10.4 Mergers and Acquisitions
 - 17.10.5 Certifications

17.11 Viatris Inc.

- 17.11.1 Financial Analysis
- 17.11.2 Product Portfolio
- 17.11.3 Demographic Reach and Achievements
- 17.11.4 Mergers and Acquisitions
- 17.11.5 Certifications
- 17.12 Amneal Pharmaceuticals LLC
 - 17.12.1 Financial Analysis
 - 17.12.2 Product Portfolio
 - 17.12.3 Demographic Reach and Achievements
 - 17.12.4 Mergers and Acquisitions
 - 17.12.5 Certifications
- 17.13 Bayer AG
 - 17.13.1 Financial Analysis
 - 17.13.2 Product Portfolio
 - 17.13.3 Demographic Reach and Achievements
 - 17.13.4 Mergers and Acquisitions
 - 17.13.5 Certifications
- 17.14 Allergan plc.
 - 17.14.1 Financial Analysis
 - 17.14.2 Product Portfolio
 - 17.14.3 Demographic Reach and Achievements
 - 17.14.4 Mergers and Acquisitions
 - 17.14.5 Certifications
- 17.15 Agile Therapeutics
 - 17.15.1 Financial Analysis
 - 17.15.2 Product Portfolio
 - 17.15.3 Demographic Reach and Achievements
 - 17.15.4 Mergers and Acquisitions
 - 17.15.5 Certifications
- 18 Global Contraceptive Pills Market Distribution Model (Additional Insight)
 - 18.1 Overview
 - 18.2 Potential Distributors
 - 18.3 Key Parameters for Distribution Partner Assessment
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 20 Company Competitiveness Analysis (Additional Insight)

- 20.1 Very Small Companies
- 20.2 Small Companies
- 20.3 Mid-Sized Companies
- 20.4 Large Companies
- 20.5 Very Large Companies
- 21 Payment Methods (Additional Insight)
 - 21.1 Government Funded
 - 21.2 Private Insurance
 - 21.3 Out-of-Pocket



Global Contraceptive Pills Market Report and Forecast 2023-2031

Market Report | 2023-04-18 | 147 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License		Price
	Single User License		\$5999.00
	Five User License		\$7999.00
	Corporate License		\$9999.00
		VAT	
		Total	

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346. []** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	Phone*	
First Name*	Last Name*	
Job title*		
Company Name*	EU Vat / Tax ID / NIP number*	
Address*	City*	
Zip Code*	Country*	
	Date	2025-05-07
	Signature	

Scotts International. EU Vat number: PL 6772247784